Pharmaceutical

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.

Apr 27, 2024 - 00:00
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.
Read the original article

Tags:

Previous Article

The privileged status of orphan medicines in Germany

Next Article

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy

Hemogenyx gets reprieve as FDA lifts clinical hold on A...

Feb 10, 2024

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT+: Vertex pain drug results met with measured optim...

Jan 30, 2024

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT+: Pharmalittle: Woodcock to retire from the FDA; A...

Nov 17, 2023